{
}
UBS analyst Danielle Antalffy has reaffirmed a Buy rating on Johnson & Johnson (NYSE: JNJ) with a price target of $180.00. The positive outlook reflects confidence in the company's performance and potential for growth in the market.
UBS analyst Danielle Antalffy has reaffirmed a Buy rating on Johnson & Johnson (NYSE: JNJ) with a price target of $180.00. The positive outlook reflects confidence in the company's performance and potential for growth in the market.
UBS has reiterated a Buy rating on AtriCure, maintaining a $60 price target despite the stock's recent decline to $34.52 following conservative guidance during the investor day. Analysts remain bullish, with price targets ranging from $45 to $66, as AtriCure aims for $750 million in sales by 2028 and a 14% EBITDA margin. The company's strong financial health and growth potential, highlighted by a 16.55% revenue increase over the past year, suggest that current market reactions may be an overreaction.
UBS has reiterated a Buy recommendation for AtriCure Inc., maintaining a price target of $60 despite a recent decline in shares following the company's conservative investor day presentation. AtriCure forecasts sales of $750 million by 2028, below consensus estimates, but analysts remain optimistic about the company's growth potential and financial health, with price targets ranging from $45 to $66. The company aims for $1 billion in revenue by 2030, focusing on product expansion and innovation to drive sustainable growth.
UBS analyst Danielle Antalffy has maintained a Buy rating on Inspire Medical Systems with a price target of $265, citing strong management discussions that bolster confidence in the company's growth despite concerns over reimbursement rates. The company reported a 57% earnings per share beat and aims for 2025 revenue of $940-955 million, reflecting its robust financial health and competitive advantages in the obstructive sleep apnea market. Other analysts also reaffirmed positive ratings, viewing any stock price dips as potential buying opportunities.
UBS analyst Danielle Antalffy has reiterated a Buy recommendation and a $265 price target for Inspire Medical Systems, indicating significant upside potential from its current price of $187.68. Despite concerns over reimbursement rates for its Inspire 5 therapy, discussions with management highlighted the company's strong market position, impressive revenue growth of 28.49%, and a robust gross profit margin of 84.68%. Analysts remain optimistic about Inspire's future, with several maintaining positive ratings and price targets, even amid ongoing legal scrutiny.
UBS has raised its price target for Baxter International shares to $35 from $32.50 while maintaining a Neutral rating. The company reported strong Q4 2024 results, with adjusted EPS of $0.58 and revenue of $2.75 billion, driven by a 50% growth in its infusion business despite challenges from Hurricane Helene. Baxter's optimistic outlook for 2025 includes expected sales growth of 5-6% and an EPS forecast of $2.45-2.55, although uncertainty remains due to the ongoing search for a new CEO.
UBS has raised Baxter International's stock price target to $35 from $32.50 while maintaining a Neutral rating. The company reported strong Q4 2024 results, with adjusted EPS of $0.58 and revenue of $2.75 billion, driven by a 50% growth in its infusion business. Despite positive guidance for 2025, uncertainty remains due to the ongoing search for a new CEO, which could impact future strategy.
UBS analyst Danielle Antalffy has raised the price target for Medtronic, Inc. (MDT) to $95. This adjustment reflects the firm's updated outlook on the company's performance in the market.
UBS analyst Danielle Antalffy has raised the price target for Medtronic, Inc. (MDT) to $93 from $90, maintaining a Neutral rating. The company reported solid F2Q25 results, with organic sales growth exceeding consensus by approximately 0.5%, contributing to a slight EPS upside. With ongoing momentum in Diabetes and a new product cycle, particularly the Affera in Cardiac Ablation Solutions, there is increased confidence in MDT"s ability to sustain growth and improve leverage over time.
Danielle Antalffy
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating and price target for johnson and johnson
16:49 04.04.2025
ubs maintains buy rating and price target for johnson and johnson
15:07 01.04.2025
ubs maintains buy rating on atricure with optimistic long term outlook
15:46 27.03.2025
ubs maintains buy rating for atricure with price target of sixty dollars
15:14 27.03.2025
ubs maintains buy rating on inspire medical with strong growth outlook
16:36 03.03.2025
ubs maintains buy rating and price target for inspire medical shares
15:44 03.03.2025
ubs raises baxter price target amid strong quarterly results and outlook
United States Dollar
Baxter International Inc. and Subs Incentive Investment Plan
USA
Danielle Antalffy
22:56 24.02.2025
ubs raises baxter stock price target amid strong fourth quarter results
United States Dollar
Baxter International Inc. and Subs Incentive Investment Plan
The Goldman Sachs Group, Inc.
USA
Joe Biden
Danielle Antalffy
22:54 24.02.2025
ubs raises medtronic price target to ninety five dollars
15:27 19.02.2025
ubs raises medtronic price target to ninety three dollars amid growth momentum
04:22 20.11.2024
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Global Trade Developments
Retail and Consumer Goods
Supply Chain Management
Stock Market Updates
Government Economic Policies
Private Equity Deals
Industry Mergers & Acquisitions
Venture Capital Investments
Fintech Startups
Funding Rounds & Investments
Energy Sector Developments
IPOs & SPACs
AI Innovations
Emerging Startups
Decentralized Finance (DeFi) Innovations
Inflation and Monetary Impact
Economic Indicators
Countries:
Companies:
Apple Inc.
NVIDIA Corp
Mastercard Inc
Tesmec S.p.A.
Ripple USD USD
The Goldman Sachs Group, Inc.
Visa Inc.
Micron Technology, Inc.
SWIGGY LIMITED
SAP SE
Ather Energy Ltd.
GLOE Inc.
Microsoft Corporation
J.P. Morgan Fixed Income Opps A EUR Inc
S&P 500
J&T EXPRESS-W
NAURA Technology Group Co., Ltd.
Bajaj Auto Limited
OLA ELECTRIC MOBILITY LTD
Teradyne, Inc.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
Saudi Riyal
United Arab Emirates Dirham
New Zealand Dollar
British Pound Sterling
Canadian Dollar
Indonesian Rupiah
South Korean Won
Malaysian Ringgit
Brazilian Real
Swiss Franc
Qatari Riyal
Bangladeshi Taka
Kuwaiti Dinar
Singapore Dollar
People: